We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+12.33%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.81B
AUM Growth
+$59.5M
Cap. Flow
-$70.5M
Cap. Flow %
-3.88%
Top 10 Hldgs %
73.95%
Holding
42
New
–
Increased
9
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$5.78M
2
EHTH icon
eHealth
EHTH
+$5.75M
3
BIIB icon
Biogen
BIIB
+$5.57M
4
ABMD
Abiomed Inc
ABMD
+$2.67M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$2.51M

Top Sells

Rank Stock Value
1
STAA icon
STAAR Surgical
STAA
+$71.9M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$24.1M
3
PRTA icon
Prothena Corp
PRTA
+$344K

Sector Composition

Rank Sector Weight
1 Healthcare 95.6%
2 Financials 3.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STAA icon
1
STAAR Surgical
STAA
$1.25B
$193M 10.65%
1,267,811
-546,100
-30% -$71.9M
BMRN icon
2
BioMarin Pharmaceuticals
BMRN
$13.3B
$185M 10.18%
2,212,950
+7,200
+0.3% +$571K
ABMD
3
DELISTED
Abiomed Inc
ABMD
$182M 10.04%
583,933
+8,700
+2% +$2.67M
INSM icon
4
Insmed
INSM
$29.4B
$171M 9.44%
6,019,106
+194,599
+3% +$5.78M
BIIB icon
5
Biogen
BIIB
$30.6B
$125M 6.9%
361,600
+18,400
+5% +$5.57M
UTHR icon
6
United Therapeutics
UTHR
$22.7B
$123M 6.79%
687,206
– –
FOLD
7
DELISTED
Amicus Therapeutics
FOLD
$96.4M 5.31%
10,002,443
+241,400
+2% +$2.36M
RVNC
8
DELISTED
Revance Therapeutics, Inc.
RVNC
$94.9M 5.23%
3,201,866
– –
PRTA icon
9
Prothena Corp
PRTA
$468M
$89M 4.91%
1,731,482
-11,023
-0.6% -$344K
VNDA icon
10
Vanda Pharmaceuticals
VNDA
$304M
$81.6M 4.49%
3,791,805
– –
EHTH icon
11
eHealth
EHTH
$40.4M
$66.9M 3.69%
1,145,870
+87,500
+8% +$5.75M
ACAD icon
12
Acadia Pharmaceuticals
ACAD
$5.06B
$57M 3.14%
2,337,877
– –
EPZM
13
DELISTED
Epizyme, Inc
EPZM
$57M 3.14%
6,856,513
– –
KPTI icon
14
Karyopharm Therapeutics
KPTI
$44.4M
$55.6M 3.06%
358,870
+1,293
+0.4% +$188K
SAGE
15
DELISTED
Sage Therapeutics
SAGE
$34.1M 1.88%
600,500
– –
ALGN icon
16
Align Technology
ALGN
$12.5B
$33.9M 1.87%
55,405
– –
CLVS
17
DELISTED
Clovis Oncology, Inc.
CLVS
$26M 1.43%
4,484,411
– –
GRTS
18
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$21.5M 1.19%
2,356,282
+57,900
+3% +$535K
ALXN
19
DELISTED
Alexion Pharmaceuticals
ALXN
$17.4M 0.96%
94,850
-140,426
-60% -$24.1M
GOSS icon
20
Gossamer Bio
GOSS
$86.1M
$14.4M 0.79%
1,772,950
– –
PBYI icon
21
Puma Biotechnology
PBYI
$442M
$12.8M 0.7%
1,392,997
– –
DRNA
22
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$12.4M 0.68%
332,713
– –
ALKS icon
23
Alkermes
ALKS
$8.29B
$11.9M 0.66%
487,100
– –
ANAB icon
24
AnaptysBio
ANAB
$1.64B
$11.3M 0.62%
436,592
– –
SNDX icon
25
Syndax Pharmaceuticals
SNDX
$1.82B
$6.89M 0.38%
401,100
+136,900
+52% +$2.51M
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return

Palo Alto Investors's Q2 2021 Portfolio in Review

As of Q2 2021, Palo Alto Investors held 42 positions worth $1.81B, up 3.4% from $1.76B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Palo Alto Investors withdrew a net $70.5M in Q2 2021, reducing 3 holdings. Its largest reduction was STAAR Surgical, cutting an estimated $71.9M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Financials.

Against the trend, Palo Alto Investors added an estimated $5.78M to Insmed.

  • Palo Alto Investors added most to Insmed in Q2 2021, an estimated $5.78M increase.
  • Palo Alto Investors's biggest Q2 2021 reduction was STAAR Surgical, cutting an estimated $71.9M.
  • Palo Alto Investors's ten largest holdings make up 74% of its $1.81B portfolio in Q2 2021.
  • Palo Alto Investors opened 0 new positions and closed 0 in Q2 2021.
  • Palo Alto Investors's portfolio value rose 3.4% quarter-over-quarter to $1.81B.

Based on Palo Alto Investors's 13F filing for Q2 2021, filed 16 Aug 2021.